Healthcare Industry News: non-Hodgkin lymphom
News Release - September 17, 2018
ORIC Pharmaceuticals Appoints Pratik Multani, MD, as Chief Medical OfficerSAN FRANCISCO, Sept. 17, 2018 -- (Healthcare Sales & Marketing Network) -- ORIC Pharmaceuticals, a clinical-stage oncology company focused on discovery and development of novel therapies against treatment-resistant cancers, today announced that Dr. Pratik Multani has been named Chief Medical Officer. Dr. Multani will oversee the clinical development of ORIC's lead compound, ORIC-101—a potent and selective small-molecule antagonist of the glucocorticoid receptor—as well as its pipeline of other novel agents targeting mechanisms of oncology therapy resistance.
"Dr. Multani has a multi-decade track record of leadership in oncology drug development, including advancing multiple therapeutics through clinical development and regulatory approval," said Jacob Chacko, MD, Chief Executive Officer of ORIC. "We are pleased that Dr. Multani is joining ORIC at this critical inflection point as we prepare to begin clinical studies of ORIC-101 in patients with solid tumors and continue to progress our pipeline."
"I am excited to join ORIC and work with its accomplished founders and scientists," said Dr. Multani. "Despite many new therapies, resistance remains a significant barrier to improved outcomes in most patients with advanced cancers, and ORIC is at the forefront of work to address that challenge, beginning with the glucocorticoid receptor antagonist and continuing with the rest of the pipeline."
Dr. Multani brings to ORIC more than 20 years of experience in oncology drug development and treatment of patients with cancer. Most recently, Dr. Multani served as Chief Medical Officer of Ignyta, which was acquired by Roche, where he led all development and regulatory activities related to multiple clinical stage assets, including Ignyta's lead program entrectinib, which is in a global, registrational study across 15 countries.
Prior to Ignyta, Dr. Multani was Chief Medical Officer of Fate Therapeutics, and prior to that held multiple leadership positions at Kalypsys, Kanisa, and Salmedix. Dr. Multani started his biotech career at Biogen Idec, where he was involved with the development of both Zevalin and Rituxan for treatment of non-Hodgkin lymphoma.
Prior to his career in biotech, Dr. Multani held academic and clinical positions at Harvard Medical School and at Massachusetts General Hospital. His postdoctoral training included a fellowship in hematology and oncology at Dana-Farber/Partners and an internship and residency in Internal Medicine at Massachusetts General Hospital. Dr. Multani received an MD from Harvard Medical School and an MS in clinical epidemiology from Harvard School of Public Health.
About ORIC Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.
Source: ORIC Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.